Samsung Biologics Expands Collaboration with LigaChem Biosciences to Enhance ADC Development and Manufacturing

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), announced to extend collaboration with L...

January 09, 2025 | Thursday | News
Primo Biotechnology Partners with SHINE Technologies to Distribute Ilumira® in Asia-Pacific

Primo Biotechnology (“Primo”) announced a strategic partnership with SHINE Technologies, LLC, (“SHINE”) a global leader in nuclear ...

January 09, 2025 | Thursday | News
Merck's GARDASIL® Becomes First HPV Vaccine Approved for Males in China

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the National Medical Products Administration (NMPA) of China approv...

January 09, 2025 | Thursday | News
Adcentrx Doses First Patient in Phase 1a/b Study of ADRX-0405 for Advanced Solid Tumors

 Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company advancing innovative protein conjugates for cancer and other life-thr...

January 07, 2025 | Tuesday | News
Jacobio Pharma's KRAS G12C Inhibitor Glecirasib Data Published in Nature Medicine, Showcasing Impressive Efficacy in NSCLC

Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced that the data from a registrational clinical trial of...

January 07, 2025 | Tuesday | News
Astellas’ VYLOY™ (Zolbetuximab) Approved in China for First-Line Treatment of Advanced Gastric and GEJ Cancer

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") announced that China's National Medical Products Administ...

January 06, 2025 | Monday | News
Hanx Biopharmaceuticals Doses First Patient in Australia for Phase 1 Clinical Trial of Groundbreaking Cancer Therapy HX044

Hanx Biopharmaceuticals, CO. Ltd, an innovative biotechnology company developing next-generation immunotherapies to address the challenges of unmet medical...

January 03, 2025 | Friday | News
Genesis Medtech Launches iReach Omnia, World’s First Powered Stapler with 90° Articulation, in China

Genesis Medtech is proud to announce that iReach Omnia, the world's first powered stapler with 90° articulation capability, has been approved for marke...

January 02, 2025 | Thursday | News
Innovent Biologics and Roche Partner to Advance Novel DLL3-Targeted ADC for Small Cell Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

January 02, 2025 | Thursday | News
CARsgen Therapeutics Launches Investigator-Initiated Trial in China for KJ-C2219, an Allogeneic CAR T-Cell Therapy Targeting CD19/CD20

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignan...

January 01, 2025 | Wednesday | News
BeiGene Exercises Option for DB1312/BG-C9074, Securing Global Rights to DualityBio's B7H4 Antibody-Drug Conjugate

Duality Biologics ("DualityBio") announced that, BeiGene. Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C907...

December 31, 2024 | Tuesday | News
BMS Gains FDA Approval for Opdivo Qvantig, First Subcutaneous PD-1 Inhibitor with Three-Minute Administration

-Bristol Myers Squibb (NYSE: BMY)  announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig™&nbs...

December 30, 2024 | Monday | News
IDEAYA Biosciences Acquires Global Rights to SHR-4849 DLL3-Targeting ADC in $1 Billion Agreement with Hengrui Pharma

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, an...

December 30, 2024 | Monday | News
Viracta Therapeutics Initiates Strategic Review and Halts NAVAL-1 Trial to Conserve Resources

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancer...

December 27, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close